Literature DB >> 11272541

Diastereoselective preparation and characterization of ruthenium bis(bipyridine) sulfoxide complexes.

D Hesek1, Y Inoue, S R Everitt, H Ishida, M Kunieda, M G Drew.   

Abstract

A new concept in the synthesis of optically active octahedral ruthenium complexes was realized for the first time when cis- or trans-Ru(bpy)2Cl, (cis- or trans-1) was reacted with either (R)-(+)- or (S)-(-)-methyl p-tolyl sulfoxide (2 or 3); this novel asymmetric synthesis leads to the diastereoselective formation of the ruthenium bis(bipyridine) complex cis-delta-[Ru(bpy)2(2)Cl]Cl (4) (49.6% de) or cis-lambda-[Ru(bpy)2(3)Cl]Cl (5) (48.4% de), respectively. cis- or trans-Ru(dmbpy)2Cl2 (cis- or trans-6) (dmbpy = 4,4'-dimethyl-2,2'-bipyridine) also reacts with 2 or 3, leading to the diastereoselective formation of cis-delta-[Ru(dmbpy)2(2)Cl]Cl (7) (59.5% de) or cis-lambda-[Ru(dmbpy)2(3)Cl]Cl (8) (57.2% de), respectively. The diastereoselectivity of these reactions is governed solely by the chirality of the sulfoxide nucleophile. This represents the first process by which a sigma-bonded ligand occupying only a single coordination site has had such an important influence on the stereochemical outcome of a ruthenium bis(bipyridine) complex formation. These novel complexes were fully characterized by elemental analysis and IR, UV/vis, and 1H, 13C, and 2D NMR spectroscopy. An investigation into the chiroptical properties of these novel ruthenium bis(bipyridine) sulfoxide complexes has been carried out, and circular dichroism spectra are used to assign absolute stereochemistry.

Entities:  

Year:  2000        PMID: 11272541     DOI: 10.1021/ic991059d

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  1 in total

1.  Strategy for the stereochemical assignment of tris-heteroleptic Ru(II) complexes by NMR spectroscopy.

Authors:  Xiulan Xie; Seann P Mulcahy; Eric Meggers
Journal:  Inorg Chem       Date:  2009-02-02       Impact factor: 5.165

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.